MHCD3817

antibody from Invitrogen Antibodies

Targeting: CD38

Flow cytometry

Antibody data

Submit

Validation data

Product number: MHCD3817 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD38 Monoclonal Antibody (HIT2), PE-Texas Red
Antibody type: Monoclonal
Antigen: Other
Description: The R-phycoerythrin (PE)-Texas Red conjugate permits simultaneous multicolor labeling and detection of multiple targets with excitation by a single excitation source-the 488 nm line of the argon-ion laser.
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: HIT2
Vial size: 500 µL
Storage: 4° C, store in dark

CD38 protein structure - MHCD3817 shown in red.

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 CSK expression varies in lymphocyte subsets and is associated with CSK genotype. (a) Gating strategy employed to distinguish monocytes and T cells (upper panel) and B cell subpopulations (bottom panel). (b) CSK expression decreases in peripheral B cells as they mature from transitional to memory cells (p = 0.030, Kruskal-Wallis test). CSK expression in peripheral T cells is low (p = 0.0047, Kruskal-Wallis test between the five cell subpopulations). (c) In naive B cells, the rs34933034 risk allele (A) is associated with increased CSK expression (29 subjects analyzed, Kruskal-Wallis test). Cell subpopulations were isolated from peripheral mononuclear cells by cell sorting as shown in (a). Expression analysis was performed by qPCR with cDNA synthesized from RNA of isolated subpopulations from mononuclear cells of non-genotyped blood donors (b) or haplotype-matched GaP subjects (c), the horizontal bar marks the median of the values.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 CD8 + T cells phenotype in CRC and OVC patients. A . An example of flow cytometric analysis of CD3 + CD8 + T cells analyzed for CD28 and Ki-67, upper panels, and HLA-DR and CD38, lower panels. Percentage of Ki-67 + CD8 T cells in CRC samples (n = 16) B . and OVC samples (n = 22) C . Co-expression of CD38 and HLA-DR on CD8 + T cells in CRC samples (D) and OVC samples (E) .

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 The CSK risk allele is associated with increased phospho-Lyn 508 and enhanced activation of mature B cells. (a) Phosphorylated tyrosine 508 was measured by flow cytometry in naive B cells of haplotype-matched GaP donors homozygous for either allele of the rs34933034 variant; the profiles of a risk (bold) and non risk (shadowed) subject are shown, the thin line shows the isotype control; (b) pLyn 508 in carriers of the CSK risk allele. pLyn 508 was normalized to each day average (n = 27, p = 0.0136, Mann-Whitney test, see methods for correction after multiple comparison, and supplementary Figure 1 , Kruskal-Wallis test P = 0.0569). (c) A representative experiment of calcium mobilization. Basal calcium was read for 40 seconds, before activation with anti-IgM (Fab') 2 . After at least six minutes of recording, ionomycin was used as a positive control for calcium mobilization and showed no difference between genotypes (data not shown). (d) Data from eleven different ""B"" haplotype donors was normalized to one non-risk (GG) subject for comparison on each of four separate days of experiments. The area under the curve for the first 90 seconds (similar results at four minutes) is shown, (see methods for statistical analysis). (e) IgM plasma levels in 42 subjects homozygous for the B haplotype, Kruskal-Wallis test. In every graph, the horizontal line marks the median.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 The CSK risk allele is associated with expansion of transitional B cells in umbilical cord blood. (a) B cells were defined by a CD19 + gate (with CD3/CD14/CD16 exclusion); transitional cells were defined as CD38 hi , CD10 hi . The transitional cells were further divided into early and late stage by gain of IgD and decreased CD10 in late stage transitional B cells. The panel shows a representative plot of each homozygous genotype. (b) The percentage of transitional cells in the CD19 compartment is significantly higher in homozygous risk allele carriers compared with heterozygotes, with a similar trend in comparison with wild type homozygous individuals (n = 27, Kruskal-Wallis test). (c) Among transitional cells, there is an expansion of the late transitional compartment in individuals who carry the risk allele (Kruskal-Wallis test). The horizontal line marks the median.